Patents Examined by Delbert R. Phillips
  • Patent number: 4861868
    Abstract: A method for preparing polypeptides in bacteria with an alanine rather than a methionine at the N-terminus. The DNA sequence expressed has an alanine codon immediately following from one to about three contiguous methionine codons including a translation start signal and allows for the expression of polypeptides having the amino acid sequence of, for example, naturally occurring eucaryotic proteins such as various bovine and porcine somatotropin species.
    Type: Grant
    Filed: February 22, 1985
    Date of Patent: August 29, 1989
    Assignee: Monsanto Company
    Inventor: Gwen G. Krivi
  • Patent number: 4861756
    Abstract: Certain polypeptide-phospholipid complexes consisting of the amphipathic, helical portion of human apo A and its analogs and a phospholipid are useful in the treatment of neonatal respiratory distress syndrome.
    Type: Grant
    Filed: October 26, 1988
    Date of Patent: August 29, 1989
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventor: Richard L. Jackson
  • Patent number: 4859654
    Abstract: Polypeptides and derivatives thereof containing homocyclostatine and cyclostatine are useful for inhibiting the angiotensinogen-cleaving action of the enzyme renin.
    Type: Grant
    Filed: June 1, 1988
    Date of Patent: August 22, 1989
    Assignee: Pfizer Inc.
    Inventors: Dennis J. Hoover, Robert L. Rosati
  • Patent number: 4859765
    Abstract: The present invention relates to novel synthetic antigens, conjugates and antibodies based upon specific peptide sequences and the production thereof. More particularly, the invention relates to a polypeptide which is a determinant site of a protein, the polypeptide having from 8 to 20 amino acid residues, having an amino-terminal amino acid and a carboxyl-terminal amino acid, wherein the polypeptide includes:(a) a four amino acid sequence which corresponds to the four amino acid sequence of a .beta.-turn of the protein;(b) a sequence of two to eight amino acid residues attached to the amino terminal (H.sub.2 N--) of the four amino acid sequence; and(c) a sequence of two to eight amino acid residues attached to the carboxyl terminal (--COOH) of the four amino acid sequence,wherein the amino acid residues of subparts (b) and (c) correspond to those attached to the amino terminal and the carboxyl terminal, respectively of the .beta.
    Type: Grant
    Filed: July 6, 1984
    Date of Patent: August 22, 1989
    Assignee: Syntex (U.S.A.) Inc.
    Inventors: John J. Nestor, Jr., John G. Moffatt, Hardy W. Chan
  • Patent number: 4857634
    Abstract: A synthetic peptide, suitable for use in vaccination against or diagnosis of a disease caused by an enterovirus and especially by a poliovirus, is the peptide coded for by codons 286-290 in the RNA sequence coding for the structural capsid protein VP1 of poliovirus type 3 Sabin strain or by equivalent codons of another enterovirus or is an antigenic equivalent thereof, the numbers of the codons being counted from the 5'-terminus of the nucleotide sequence coding for the VP1 capsid protein.
    Type: Grant
    Filed: August 24, 1987
    Date of Patent: August 15, 1989
    Assignee: National Research Development Corporation
    Inventors: Philip D. Minor, David M. A. Evans, Geoffrey C. Schild, Jeffrey W. Almond, Morag Ferguson
  • Patent number: 4857507
    Abstract: The invention relates to renin inhibiting compounds of the formula ##STR1## wherein A is hydrogen; loweralkyl; arylalkyl; OR.sub.10 or SR.sub.10 wherein R.sub.10 is hydrogen, loweralkyl or aminoalkyl; NR.sub.11 R.sub.12 wherein R.sub.11 and R.sub.12 are independently selected from hydrogen, loweralkyl, aminoalkyl, cyanoalkyl and hydroxyalkyl; ##STR2## wherein B is NH, alkylamino, S, O, CH.sub.2 or CHOH and R.sub.13 is loweralkyl, cycloalkyl, aryl, arylalkyl, alkoxy, alkenyloxy, hydroxyalkoxy, dihydroxyalkoxy, arylalkoxy, arylalkoxyalkyl, amino, alkylamino, dialkylamino, (hydroxyalkyl)(alkyl)amino, (dihydroxyalkyl)(alkyl)amino, aminoalkyl, alkoxycarbonylalkyl, carboxyalkyl, N-protected aminoalkyl, alkylaminoalkyl, (N-protected)(alkyl)aminoalkyl, dialkylaminoalkyl, (heterocyclic) alkyl or a substituted or unsubstituted heterocyclic; W is CO or CHOH and U is CH.sub.2 or NR.sub.2 with the proviso that when W is CHOH then U is CH.sub.2 ; R.sub.1 is loweralkyl, cycloaklylmethyl, benzyl, .alpha.,.alpha.
    Type: Grant
    Filed: January 9, 1987
    Date of Patent: August 15, 1989
    Assignee: Abbott Laboratories
    Inventors: Saul H. Rosenberg, Joseph Dellaria, Anthony K, L. Fung, Dale J. Kempf, Jay R. Luly, Jacob J. Plattner
  • Patent number: 4855286
    Abstract: The invention relates to compounds of the formula ##STR1## in which R.sup.1 is absent or denotes hydrogen, alkyl or acyl, A denotes an acyl radical or an amino acid residue, B denotes an amino acid residue, and R.sup.2, R.sup.3 and R.sup.4 are as defined in the specification, and to their salts, to a process for their preparation, to pharmaceutical products containing them, and to their use as medicaments, and intermediates for the preparation of these compounds.
    Type: Grant
    Filed: July 28, 1987
    Date of Patent: August 8, 1989
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Adalbert Wagner, Heinz-Werner Kleemann, Dieter Ruppert, Bernward Scholkens
  • Patent number: 4855406
    Abstract: Disclosed are an oncogene-related peptide characterized in that the peptide comprises a portion of the amino acid sequence of a gene product coded for by an oncogene, an antigen or immunogen formed from the oncogene-related peptide and a carrier, an antibody against such antigen or immunogen, and a method of determining a gene product coded for by an oncogene by an immunoreaction with use of such antibody.
    Type: Grant
    Filed: July 10, 1987
    Date of Patent: August 8, 1989
    Assignee: Noboru Yanaihara et al.
    Inventors: Noboru Yanaihara, Kaoru Abe
  • Patent number: 4855285
    Abstract: Endogenous and exogenous proteins, and fragments thereof, are chemically modified outside the body of an animal so that when injected into the animal they produce more antibodies against the unmodified protein than would injection of the unmodified protein or fragment alone. The chemical modification may be accomplished by attaching the proteins or fragments to carriers such as, for example, bacterial toxoids. The chemical modification can also be accomplished by polymerization of protein fragments. Proteins which can be modified include Follicle Stimulating Hormone and Human Chorionic Gonadotropin. The modified polypeptides may be administered to animals for the purpose of contraception, abortion or treatment of hormone-related disease states and disease disorders, treatment of hormone-associated carcinomas, and to boost the animals resistance to exogenous proteins, for example viral proteins.
    Type: Grant
    Filed: August 17, 1987
    Date of Patent: August 8, 1989
    Assignee: The Ohio State University Research Foundation
    Inventor: Vernon C. Stevens
  • Patent number: 4855303
    Abstract: Polypeptides containing fluorinated cyclostatine derivatives as antihypertensive agents.
    Type: Grant
    Filed: June 10, 1988
    Date of Patent: August 8, 1989
    Assignee: Pfizer Inc.
    Inventor: Dennis J. Hoover
  • Patent number: 4855409
    Abstract: A novel polypeptide which is at least equivalent in biological activity to IFN-.gamma. and is resistant to dimerization and polymerization, a transformant which carries a DNA coding for a novel polypeptide, and a method of producing a novel polypeptide from the culture of the transformant.The DNA coding for the novel polypeptide can be produced, for example, starting with a known plasmid which contains the IFN-.gamma. gene (cDNA), namely pHITtrp1101 or pHITtrp 1201.Insertion of this DNA into a vector followed by introduction into a host gives the transformant. An antibody column is used for the purification of the polypeptide from the culture.The novel polypeptide produced can be used as an antiviral agent or an antitumor agent.
    Type: Grant
    Filed: November 23, 1987
    Date of Patent: August 8, 1989
    Assignee: Takeda Chemical Industries, Ltd.
    Inventors: Kikuchi Masakazu, Kurokawa Tsutomu, Honda Susumu
  • Patent number: 4853371
    Abstract: An octapeptide of the formula: ##STR1## wherein each A.sub.1 and A.sub.2, independently, is H, C.sub.1-12 alkyl, C.sub.7-10 phenylalkyl, R.sub.1 CO (where R.sub.1 is C.sub.1-20 alkyl, C.sub.3-20 alkenyl, C.sub.3-20 alkinyl, phenyl, naphthyl, or C.sub.7-10 phenylalkyl, R.sub.2 OCO (where R.sub.2 is C.sub.1-10 alkyl or C.sub.7-10 phenylalkyl), provided that when one of A.sub.1 or A.sub.2 is R.sub.1 CO or R.sub.2 OCO, the other must be H; A.sub.3 is CH.sub.2 -A.sub.6 (where A.sub.6 is pentafluorophenyl, naphthyl, pyridyl, or phenyl); A.sub.4 is o- m- or p-substituted X-Phe (where X is a halogen, H, NO.sub.2, OH, NH.sub.2, or C.sub.1-3 alkyl), pentafluoro-Phe, or .alpha.-Nal; A.sub.5 is Thr, Ser, Phe, Val, .alpha.-aminobutyric acid, or Ile, provided that when A.sub.3 is phenyl, A.sub.1 is H, and A.sub.2 is H, A.sub.5 cannot be Val; and A.sub.7 is Thr, Trp, or .beta.-Nal; or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: June 22, 1988
    Date of Patent: August 1, 1989
    Assignee: The Administrators of the Tulane Educational Fund
    Inventors: David H. Coy, William A. Murphy, Mark L. Heiman
  • Patent number: 4853220
    Abstract: The invention relates to Tetranectin, a new protein isolated from blood. Its structure comprises four polypeptide chains having the formula shown in the attached drawing.Tetranectin plays a role in the hemostatic system and, therefore, may be used as an agent for regulation of hemostasis.Further, the invention relates to a process for preparing Tetranectin in which Tetranectin is isolated e.g. from blood or blood fractions, cells or genetically engineered organisms.Finally the invention relates to antiserum or antibodies against Tetranectin, to immunological detection and assay methods wherein said antiserum or antibodies are used as immunological reagent, and to pharmaceutical compositions containing Tetranectin or antibodies against Tetranectin.
    Type: Grant
    Filed: June 10, 1986
    Date of Patent: August 1, 1989
    Assignee: Nederlandse Centrale Organisatie Voor Toegerastnatuurwete Nschappelijk Onderzoek
    Inventors: Inge D. Clemmensen, Cornelis Kluft
  • Patent number: 4851387
    Abstract: A 5-substituted amino-4-hydroxy-pentanoic acid derivative having the formula: ##STR1## wherein R.sup.1 is a hydrogen atom or an N-protecting group, R.sup.2, R.sup.3 and R.sup.5 may be any of a variety of groups including the side chains of amino acid residues, R.sup.4 is a hydrogen atom or a lower alkyl group, R.sup.6 is a group which is substituted by one or two hydroxyl groups, and R.sup.7 is any of a variety of groups, including a hydroxyl group, which compounds are renin inhibitors useful as hypotensive drugs, are disclosed.
    Type: Grant
    Filed: October 13, 1987
    Date of Patent: July 25, 1989
    Assignee: Banyu Pharmaceutical Co., Ltd.
    Inventors: Yutaka Koike, Masato Nakano, Shugo Atsuumi, Seiichi Tanaka, Hajime Morishima, Kenji Matsuyama
  • Patent number: 4851385
    Abstract: Antagonist analogs of luteinizing hormone-releasing hormone (LHRH) having N-alkylated basic amino acid residues at the 8 position, 8 and 6 positions, 8 and 5 positions, and 8, 6 and 5 positions, having high antiovulatory activity and low histamine release activity, and their use in regulating the release of gonadatropic hormones from the pituitary gland of mannals.
    Type: Grant
    Filed: July 15, 1987
    Date of Patent: July 25, 1989
    Assignee: Indiana University Foundation
    Inventor: Roger W. Roeske
  • Patent number: 4851388
    Abstract: Peptides useful as antiinfective agents, immunomodulators for stimulation of host defenses in patients with an increased risk of bacterial infections, intermediates and process therefor.
    Type: Grant
    Filed: August 17, 1987
    Date of Patent: July 25, 1989
    Assignee: Pfizer Inc.
    Inventor: Gene M. Bright
  • Patent number: 4849408
    Abstract: The use of tryptophan containing oligopeptides for the treatment of cerebral disturbances in particular sleeplessness and depression is disclosed. The use of glycyl tryptophan, if desired, in combination with tryptophan itself, is especially preferred.
    Type: Grant
    Filed: January 7, 1987
    Date of Patent: July 18, 1989
    Assignee: (501) Fresenius AG
    Inventors: Klaus Sommermeyer, Burghard Weidler
  • Patent number: 4849358
    Abstract: There is disclosed a method for culturing Bordetella pertussis in the prece of a cellulose and/or cellulose derivatives. The present method is useful for obtaining a mixed antigen comprising pertussis toxin and filamentous hemagglutinin in a large amount at low cost. From the antigen, there can be obtained a stable and effective pertussis toxoid to be used for a pertussis vaccine. There is also disclosed a vaccine comprising the pertussis toxoid as an active ingredient and a gelatin and/or gelatin derivatives as a stabilizing agent. The present vaccine is extremely stable and can be stored for a prolonged period of time.
    Type: Grant
    Filed: July 14, 1987
    Date of Patent: July 18, 1989
    Assignee: The Research Foundation for Microbial Diseases of Osaka University
    Inventors: Masashi Chazono, Iwao Yoshida, Takeo Konobe, Juichiro Osame, Keisuke Takaku
  • Patent number: 4849407
    Abstract: Dimeric proteins having substantially the same biological activity as PDGF are disclosed. More specifically, the proteins may have two polypeptide chains, one of the chains being a mosaic of amino acid sequences substantially identical to portions of the A- or B-chains of PDGF, the second of the chains being substantially homologous to either the A-chain or the B-chain of PDGF, the proteins being chemotactic or mitogenic for fibroblasts. Alternatively, each of the two polypeptide chains may be a mosaic of amino acid sequences as described above. Therapeutic compositions containing these proteins and methods for enhancing the wound-healing process in warm-blooded animals are also disclosed.
    Type: Grant
    Filed: December 15, 1986
    Date of Patent: July 18, 1989
    Assignee: ZymoGenetics, Inc.
    Inventors: Mark J. Murray, James D. Kelly
  • Patent number: RE32992
    Abstract: The invention deals with novel peptides useful for the therapeutic treatment of infectious diseases caused by pathogenic microorganisms. Included is the peptide FR900156 having the structure: ##STR1## as well as the peptides of the structure ##STR2## wherein R.sup.1 is acyl;R.sub.b.sup.1 is hydrogen, methyl, isopropyl, hydroxymethyl, protected hydroxymethyl or benzyl;R.sup.2 is hydrogen, carboxy, protected carboxy, or a group of the formula: ##STR3## wherein R.sub.a.sup.2 is mono- or di-carboxy lower alkyl or ar(carboxy) lower alkyl whose aryl moiety may be substituted by hydroxy,R.sub.b.sup.2 is hydrogen or lower alkyl;R.sup.p and R.sup.q are each hydrogen, carboxy, protected carboxy, with proviso that when one of R.sup.2 and R.sup.q is hydrogen, then the other is carboxy or protected carboxy;R.sup.r is hydrogen or amino protective group; m is an integer 1 to 3, and n is 1 .Iadd.provided that when R.sup.1 is benzyloxycarbonyl R.sub.5.sup.1 is methyl, m is an integer 2 and n is an integer 1, then R.sup.
    Type: Grant
    Filed: May 18, 1984
    Date of Patent: July 18, 1989
    Assignee: Fujisawa Pharaceutical Co., Ltd.
    Inventors: Yoshio Kuroda, Eiko Iguchi, Masanobu Kohsaka, Hatsuo Aoki, Hiroshi Imanaka, Yoshihiko Kitaura, Osamu Nakaguchi, Keiji Hemmi, Matsuhiko Aratani, Hidekazu Takeno, Satoshi Okada, Hirokazu Tanaka, Masashi Hashimoto